PHARMACOTHERAPY PROFILE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN ELDERLY PATIENTS AT RSUP PROF DR. I.G.N.G NGOERAH DURING THE PERIOD OF JANUARY 2023 – DECEMBER 2023

Abstract

Introduction: Chronic Obstructive Pulmonary Disease (COPD) is a global health issue that is often undiagnosed, particularly among the elderly. Furthermore, elderly patients with comorbidities may receive multiple and varied therapies to address their conditions, which can lead to complex polypharmacy. Therefore, research is needed to describe pharmacotherapy profile of COPD in elderly patients. Objective: To describe the pharmacotherapy profile of COPD in elderly patients at Prof. dr. I.G.N.G Ngoerah Hospital. Methods: This study employs a descriptive quantitative method with a cross-sectional approach, with samples taken retrospectively from the medical records of elderly COPD patients at Prof. dr. I.G.N.G Ngoerah Hospital in 2023, according to inclusion and exclusion criteria. Data was collected via Google Forms and analyzed using Microsoft Excel. Results: The most used COPD therapy regimen is the LABA-ICS combination, specifically the combination of salmeterol and fluticasone propionate (54.2%) followed by the combination of budesonide and formoterol fumarate (26.5%). Supportive therapy commonly administered to patients, include mucolytic agents such as N-acetylcysteine (61.4%) and ambroxol (22.8%). The most common comorbidity diagnosed among COPD elderly patient was cardiovascular disease (54.3%), with most patients receiving beta-blocker medications that have the potential to cause drug interactions with β2-agonists. Conclusion: The use of dual LABA-ICS combinations with additional symptomatic therapy in the form of mucolytics such as N-acetylcysteine and ambroxol is the most common choice for controller therapy for outpatient elderly COPD patients at Prof. dr. I.G.N.G Ngoerah Hospital.